Our triple FluoroSpot Plus: Human IFN-γ/IL-2/TNF-α has gotten its first citation. Authors Fostier et al. (Oncotarget, 2018) utilized FluoroSpot to be able to show a more polyfunctional profile of CD8+ T cells in patients with multiple myeloma after lenolidomide treatment.
The increased potential anti-myeloma effect of the multipotent CD8+ T cells seemed however to be hampered by the concurrent rise in number of Tregs. The authors conclude that interventions aimed at reducing Treg expansion during lenalidomide treatment may improve further anti-tumor vaccinations.